Jeffery Chadbourne - IDEXX Laboratories Director Reporting
| IDXX Stock | USD 421.76 0.00 0.00% |
Insider
Jeffery Chadbourne is Director Reporting of IDEXX Laboratories
| Age | 48 |
| Address | One IDEXX Drive, Westbrook, ME, United States, 04092 |
| Phone | 207 556 0300 |
| Web | https://www.idexx.com |
IDEXX Laboratories Management Efficiency
The company has return on total asset (ROA) of 0.2279 % which means that it generated a profit of $0.2279 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.5942 %, meaning that it created $0.5942 on every $100 dollars invested by stockholders. IDEXX Laboratories' management efficiency ratios could be used to measure how well IDEXX Laboratories manages its routine affairs as well as how well it operates its assets and liabilities. At this time, IDEXX Laboratories' Return On Tangible Assets are fairly stable compared to the past year. Return On Assets is likely to rise to 0.27 in 2024, whereas Return On Capital Employed is likely to drop 0.26 in 2024. At this time, IDEXX Laboratories' Return On Assets are fairly stable compared to the past year.Similar Executives
| Showing other executives | INSIDER Age | ||
| C Harris | Thermo Fisher Scientific | 64 | |
| Jiang Wei | Waters | N/A | |
| Mikael Dolsten | Agilent Technologies | 62 | |
| Allison Ballmer | Agilent Technologies | N/A | |
| Dan Welch | Waters | 58 | |
| Aaron Sato | Twist Bioscience Corp | N/A | |
| Dana Snr | ICON PLC | N/A | |
| Pearl Huang | Waters | 62 | |
| Padraig McDonnell | Agilent Technologies | 49 | |
| Christopher Bouda | Danaher | N/A | |
| Susan Tousi | Illumina | 55 | |
| Jessica Mega | Danaher | 46 | |
| Jeffrey Spaeder | IQVIA Holdings | N/A | |
| JoseCarlos GutierrezRamos | Danaher | 62 | |
| Thomas OLeary | ICON PLC | N/A | |
| Keeley Aleman | Waters | 47 | |
| Dr MBA | ICON PLC | 64 | |
| Domitille Bigot | Mettler Toledo International | 48 | |
| Costa Panagos | IQVIA Holdings | N/A | |
| Sandy Pound | Thermo Fisher Scientific | N/A | |
| Kevin Yankton | Twist Bioscience Corp | 57 | |
Management Performance
| Return On Equity | 0.59 | ||||
| Return On Asset | 0.23 |
IDEXX Laboratories Leadership Team
Elected by the shareholders, the IDEXX Laboratories' board of directors comprises two types of representatives: IDEXX Laboratories inside directors who are chosen from within the company, and outside directors, selected externally and held independent of IDEXX. The board's role is to monitor IDEXX Laboratories' management team and ensure that shareholders' interests are well served. IDEXX Laboratories' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, IDEXX Laboratories' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Sharon JD, General VP | ||
| Nimrata PE, Sector Strategy | ||
| Martin Smith, Executive CTO | ||
| Michael Lane, Corporate Vice President General Manager | ||
| Jeffery Chadbourne, Director Reporting | ||
| George Fennell, Senior Officer | ||
| Sharon Underberg, Corporate Vice President General Counsel, and Corporate Secretary | ||
| Ken Grady, Senior Officer | ||
| Kerry Bennett, Senior Labs | ||
| Michael Johnson, Executive Officer | ||
| Jonathan Mazelsky, CEO President | ||
| James Polewaczyk, Executive Officer | ||
| John Hart, Senior Operations | ||
| Michael Erickson, Executive Telemedicine | ||
| Brian McKeon, CFO, Principal Accounting Officer, Executive VP and Treasurer |
IDEXX Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is IDEXX Laboratories a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.59 | ||||
| Return On Asset | 0.23 | ||||
| Profit Margin | 0.23 % | ||||
| Operating Margin | 0.37 % | ||||
| Current Valuation | 34.86 B | ||||
| Shares Outstanding | 81.88 M | ||||
| Shares Owned By Insiders | 0.94 % | ||||
| Shares Owned By Institutions | 94.22 % | ||||
| Number Of Shares Shorted | 2.08 M | ||||
| Price To Earning | 61.31 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for IDEXX Stock Analysis
When running IDEXX Laboratories' price analysis, check to measure IDEXX Laboratories' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IDEXX Laboratories is operating at the current time. Most of IDEXX Laboratories' value examination focuses on studying past and present price action to predict the probability of IDEXX Laboratories' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IDEXX Laboratories' price. Additionally, you may evaluate how the addition of IDEXX Laboratories to your portfolios can decrease your overall portfolio volatility.